US Patent Issued to Gilead Sciences on Feb. 24 for "Methods of identifying HIV patients sensitive to therapy with gp120 CD4 binding site-directed antibodies" (Belgian, American Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,546, issued on Feb. 24, was assigned to Gilead Sciences Inc. (Foster City, Calif.).

"Methods of identifying HIV patients sensitive to therapy with gp120 CD4 binding site-directed antibodies" was invented by Stephen R. Martin (Tiburon, Calif.), Brian Moldt (Overijse, Belgium) and Aiyappa Parvangada (San Mateo, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region."

The patent was filed on Nov. 9, 2021, under Application No. 17/522,648.

*For further information, including images, charts ...